Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

J. R. Brahmer, J. W. Lee, A. M. Traynor, M. M. Hidalgo, J. M. Kolesar, J. M. Siegfried, P. P. Guaglianone, J. D. Patel, M. D. Keppen, J. H. Schiller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background The development of a rash has been retrospectively associated with increased response and improved survival when treated with erlotinib at the standard dose of 150 mg per day. The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced non-small-cell lung cancer (NSCLC) with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. Methods Patients, with advanced NSCLC without prior systemic therapy, were treated with erlotinib 150 mg orally per day. The dose was increased by 25 mg every two weeks until the development of grade 2/tolerable rash or other dose limiting toxicity. Tumour biopsy specimens were required for inclusion. Results The study enrolled 137 patients, 135 were evaluable for safety and 124 were eligible and evaluable for response. Only 73 tumour samples were available for analysis. Erlotinib dose escalation occurred in 69/124 patients. Erlotinib was well tolerated with 70% of patients developing a grade 1/2 rash and 10% developing grade 3 rash. Response rate and disease control rate were 6.5% and 41.1% respectively. Median overall survival was 7.7 months. Toxicity and tumour markers were not associated with response. Grade 2 or greater skin rash and low phosphorylated mitogen-activated protein kinase (pMAPK) were associated with improved survival. Conclusions Overall survival was similar in this trial compared to first-line chemotherapy in this unselected patient population. Dose escalation to the development of grade 2 skin rash was associated with improved survival in this patient population.

Original languageEnglish (US)
Pages (from-to)302-308
Number of pages7
JournalEuropean Journal of Cancer
Volume50
Issue number2
DOIs
StatePublished - Jan 2014

Fingerprint

Exanthema
Non-Small Cell Lung Carcinoma
Survival
Neoplasms
Tumor Biomarkers
Erlotinib Hydrochloride
Mitogen-Activated Protein Kinases
Population
Biopsy
Safety
Drug Therapy

Keywords

  • Erlotinib
  • NSCLC
  • Phase II

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dosing to rash : A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). / Brahmer, J. R.; Lee, J. W.; Traynor, A. M.; Hidalgo, M. M.; Kolesar, J. M.; Siegfried, J. M.; Guaglianone, P. P.; Patel, J. D.; Keppen, M. D.; Schiller, J. H.

In: European Journal of Cancer, Vol. 50, No. 2, 01.2014, p. 302-308.

Research output: Contribution to journalArticle

Brahmer, JR, Lee, JW, Traynor, AM, Hidalgo, MM, Kolesar, JM, Siegfried, JM, Guaglianone, PP, Patel, JD, Keppen, MD & Schiller, JH 2014, 'Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)', European Journal of Cancer, vol. 50, no. 2, pp. 302-308. https://doi.org/10.1016/j.ejca.2013.10.006
Brahmer, J. R. ; Lee, J. W. ; Traynor, A. M. ; Hidalgo, M. M. ; Kolesar, J. M. ; Siegfried, J. M. ; Guaglianone, P. P. ; Patel, J. D. ; Keppen, M. D. ; Schiller, J. H. / Dosing to rash : A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). In: European Journal of Cancer. 2014 ; Vol. 50, No. 2. pp. 302-308.
@article{4f97aab9830a43779dd68bfd90c8b273,
title = "Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)",
abstract = "Background The development of a rash has been retrospectively associated with increased response and improved survival when treated with erlotinib at the standard dose of 150 mg per day. The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced non-small-cell lung cancer (NSCLC) with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. Methods Patients, with advanced NSCLC without prior systemic therapy, were treated with erlotinib 150 mg orally per day. The dose was increased by 25 mg every two weeks until the development of grade 2/tolerable rash or other dose limiting toxicity. Tumour biopsy specimens were required for inclusion. Results The study enrolled 137 patients, 135 were evaluable for safety and 124 were eligible and evaluable for response. Only 73 tumour samples were available for analysis. Erlotinib dose escalation occurred in 69/124 patients. Erlotinib was well tolerated with 70{\%} of patients developing a grade 1/2 rash and 10{\%} developing grade 3 rash. Response rate and disease control rate were 6.5{\%} and 41.1{\%} respectively. Median overall survival was 7.7 months. Toxicity and tumour markers were not associated with response. Grade 2 or greater skin rash and low phosphorylated mitogen-activated protein kinase (pMAPK) were associated with improved survival. Conclusions Overall survival was similar in this trial compared to first-line chemotherapy in this unselected patient population. Dose escalation to the development of grade 2 skin rash was associated with improved survival in this patient population.",
keywords = "Erlotinib, NSCLC, Phase II",
author = "Brahmer, {J. R.} and Lee, {J. W.} and Traynor, {A. M.} and Hidalgo, {M. M.} and Kolesar, {J. M.} and Siegfried, {J. M.} and Guaglianone, {P. P.} and Patel, {J. D.} and Keppen, {M. D.} and Schiller, {J. H.}",
year = "2014",
month = "1",
doi = "10.1016/j.ejca.2013.10.006",
language = "English (US)",
volume = "50",
pages = "302--308",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Dosing to rash

T2 - A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

AU - Brahmer, J. R.

AU - Lee, J. W.

AU - Traynor, A. M.

AU - Hidalgo, M. M.

AU - Kolesar, J. M.

AU - Siegfried, J. M.

AU - Guaglianone, P. P.

AU - Patel, J. D.

AU - Keppen, M. D.

AU - Schiller, J. H.

PY - 2014/1

Y1 - 2014/1

N2 - Background The development of a rash has been retrospectively associated with increased response and improved survival when treated with erlotinib at the standard dose of 150 mg per day. The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced non-small-cell lung cancer (NSCLC) with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. Methods Patients, with advanced NSCLC without prior systemic therapy, were treated with erlotinib 150 mg orally per day. The dose was increased by 25 mg every two weeks until the development of grade 2/tolerable rash or other dose limiting toxicity. Tumour biopsy specimens were required for inclusion. Results The study enrolled 137 patients, 135 were evaluable for safety and 124 were eligible and evaluable for response. Only 73 tumour samples were available for analysis. Erlotinib dose escalation occurred in 69/124 patients. Erlotinib was well tolerated with 70% of patients developing a grade 1/2 rash and 10% developing grade 3 rash. Response rate and disease control rate were 6.5% and 41.1% respectively. Median overall survival was 7.7 months. Toxicity and tumour markers were not associated with response. Grade 2 or greater skin rash and low phosphorylated mitogen-activated protein kinase (pMAPK) were associated with improved survival. Conclusions Overall survival was similar in this trial compared to first-line chemotherapy in this unselected patient population. Dose escalation to the development of grade 2 skin rash was associated with improved survival in this patient population.

AB - Background The development of a rash has been retrospectively associated with increased response and improved survival when treated with erlotinib at the standard dose of 150 mg per day. The objective of this trial was to evaluate the association of the activity of erlotinib in the first-line setting in patients with advanced non-small-cell lung cancer (NSCLC) with the development of a tolerable rash via dose escalation of erlotinib or tumour characteristics. Methods Patients, with advanced NSCLC without prior systemic therapy, were treated with erlotinib 150 mg orally per day. The dose was increased by 25 mg every two weeks until the development of grade 2/tolerable rash or other dose limiting toxicity. Tumour biopsy specimens were required for inclusion. Results The study enrolled 137 patients, 135 were evaluable for safety and 124 were eligible and evaluable for response. Only 73 tumour samples were available for analysis. Erlotinib dose escalation occurred in 69/124 patients. Erlotinib was well tolerated with 70% of patients developing a grade 1/2 rash and 10% developing grade 3 rash. Response rate and disease control rate were 6.5% and 41.1% respectively. Median overall survival was 7.7 months. Toxicity and tumour markers were not associated with response. Grade 2 or greater skin rash and low phosphorylated mitogen-activated protein kinase (pMAPK) were associated with improved survival. Conclusions Overall survival was similar in this trial compared to first-line chemotherapy in this unselected patient population. Dose escalation to the development of grade 2 skin rash was associated with improved survival in this patient population.

KW - Erlotinib

KW - NSCLC

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=84891827637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891827637&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.10.006

DO - 10.1016/j.ejca.2013.10.006

M3 - Article

C2 - 24246704

AN - SCOPUS:84891827637

VL - 50

SP - 302

EP - 308

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 2

ER -